SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences informs about press release

04 Jun 2026 Evaluate
Suven Life Sciences has informed that it enclosed News Release of the company titled ‘Suven Life Sciences Reports Positive DSMB Safety Review and Interim Analysis from Ongoing Global Phase 3 Study of Masupirdine in Alzheimer's Disease Agitation at 50% study completers - Study to Continue Unchanged’.

The above information is a part of company’s filings submitted to BSE.

Suven Life Sciences Share Price

266.40 -8.75 (-3.18%)
04-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.35
Dr. Reddys Lab 1267.05
Cipla 1397.75
Zydus Lifesciences 1085.45
Lupin 2248.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×